Pin30 Substitution to Lopinavir/Ritonavir (Lpv/R) Is Associated With Improved Patient-Reported Fatigue in Hiv+ Patients Experiencing Side Effects Related to Their Protease Inhibitor (Pi)/Non-Nucleoside Reverse Transcriptase Inhibitor (Nnrti)

Luo, MP; Shen, Yang; Rode, RA; McMillan, F; Tressler, Randall; Ashraf, Talat

doi:10.1016/s1098-3015(10)62499-0

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence of diarrhea due to lopinavir/ritonavir is higher than that due to atazanavir (Johnson et al 2005). However, patients who switched therapy from another PI-based regimen to lopinavir/ ritonavir based regimen showed an overall improvement in side effects and health related quality of life (Luo et al 2004). Immune reconstitution syndrome has been reported in patients treated with antiretroviral regimens containing lopinavir/ritonavir, manifested as an infl ammatory response to indolent opportunistic infections.…”

Section: Adverse Reactionsmentioning

confidence: 99%

Lopinavir/ritonavir in the treatment of HIV-1 infection: a review

Chandwani

Shuter²

2008

TCRM

196

View full text Add to dashboard Cite

Lopinavir/ritonavir is the fi rst and only coformulated HIV-1 protease inhibitor (PI). Large clinical trials have demonstrated lopinavir/ritonavir's clinical effi cacy in both antiretroviral-naïve and -experienced patients. The immunologic and virologic benefi ts of treatment with this agent have been proven in HIV-infected adults, adolescents, and children. Smaller studies support the use of lopinavir/ritonavir monotherapy as a therapeutic option in certain patients. The drug is characterized by a high genetic barrier to resistance, and appears to be more forgiving of non-adherence than earlier, unboosted PIs. The most frequent side effects observed are diarrhea, nausea, and vomiting. These gastrointestinal adverse effects are generally mild to moderate. Metabolic derangements, including hyperlipidemia and glucose intolerance, have also been observed in lopinavir/ritonavir recipients. As the menu of available antiretroviral agents continues to expand, lopinavir/ritonavir remains a proven and effective drug for the treatment of HIV infection.

show abstract

Section: Adverse Reactionsmentioning

confidence: 99%